dabigatran has been researched along with Heart Valve Diseases in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (87.50) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, MS; Choi, KJ; Kang, DH; Kim, DH; Kim, J; Kim, M; Kim, SJ; Lee, S; Lee, SA; Nam, GB; Song, JM | 1 |
| Beauchesne, LM; Bouma, BJ; Khairy, P; Macle, L; Mongeon, FP; Mulder, BJM; Schwerzmann, M | 1 |
| Hung, CS; Li, HJ; Lin, FJ; Lin, SY; Wang, CC | 1 |
| Balsam, P; Bednarski, J; Maciejewski, K; Opolski, G; Ozierański, K; Peller, M; Praska-Oginska, A; Szepietowska, K; Tymińska, A; Zaboyska, I; Zaleska, M; Żukowska, K | 1 |
| Akintoye, E; Alvarez, P; Briasoulis, A; Inampudi, C; Panaich, S; Vaughan-Sarrazin, M | 1 |
| Dalen, JE | 1 |
| Bonner, E; Finsterer, J; Stöllberger, C | 1 |
| Garg, P; Ripley, DP | 1 |
| Otto, CM | 1 |
| Brueckmann, M; Clemens, A; Connolly, SJ; Ezekowitz, MD; Jacobs, M; Litherland, C; Nagarakanti, R; Noack, H; Reilly, PA; Wallentin, L; Yusuf, S | 1 |
| Chillarige, Y; Goulding, MR; Graham, DJ; Hsueh, YH; Izem, R; Kelman, JA; Liao, J; MaCurdy, TE; Mott, K; Reichman, ME; Southworth, MR; Wei, Y; Wernecke, M; Worrall, C | 1 |
| Breithardt, G | 1 |
| Boodhwani, M; Mastrobuoni, S; Robblee, JA | 1 |
| Ansell, J; Mantha, S | 1 |
| Bunton, R; Chen, VH; Chu, JW | 1 |
| Boodhwani, M; Hynes, M; Labinaz, M; Price, J; Ruel, M | 1 |
2 review(s) available for dabigatran and Heart Valve Diseases
| Article | Year |
|---|---|
Non-Vitamin K Antagonist Oral Anticoagulants in Adult Congenital Heart Disease.
Topics: Administration, Oral; Adult; Age Factors; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Female; Heart Defects, Congenital; Heart Valve Diseases; Humans; Male; Prognosis; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Severity of Illness Index; Sex Factors; Stroke; Survival Analysis; Thiazoles; Vitamin K | 2019 |
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Heart Valve Diseases; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Vitamin K; Warfarin | 2012 |
2 trial(s) available for dabigatran and Heart Valve Diseases
| Article | Year |
|---|---|
Comparison of Dabigatran Versus Warfarin Treatment for Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Heart Valve Diseases; Humans; Stroke; Treatment Outcome; Warfarin | 2022 |
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Administration Schedule; Female; Heart Valve Diseases; Humans; Male; Prospective Studies; Retrospective Studies; Time Factors; Warfarin | 2016 |
12 other study(ies) available for dabigatran and Heart Valve Diseases
| Article | Year |
|---|---|
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation and valvular heart disease.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Heart Valve Diseases; Humans; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome | 2021 |
District versus academic hospitals: differences in the clinical characteristics of patients with atrial fibrillation without valvular heart disease treated with oral anticoagulants
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Heart Valve Diseases; Hospitals, District; Hospitals, University; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thromboembolism | 2018 |
Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Heart Valve Diseases; Humans; Male; Medicare; Retrospective Studies; Rivaroxaban; Thromboembolism; Treatment Outcome; United States; Warfarin | 2018 |
Should the newer oral anticoagulants be withheld from patients with valvular AF?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; Humans; International Normalized Ratio; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Enterococcus faecalis bacteremia and mitral valve endocarditis under dabigatran for stroke prevention.
Topics: Aged; Bacteremia; Benzimidazoles; beta-Alanine; Dabigatran; Endocarditis; Enterococcus faecalis; Fatal Outcome; Female; Gram-Positive Bacterial Infections; Heart Valve Diseases; Humans; Mitral Valve; Stroke | 2014 |
Defining non-valvular atrial fibrillation while selecting anticoagulation therapy.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2015 |
Heartbeat: Echo anytime, anywhere by anyone?
Topics: Antithrombins; Clinical Competence; Dabigatran; Echocardiography; Equipment Design; Heart Valve Diseases; Humans; Lipid Metabolism; Point-of-Care Systems; Point-of-Care Testing; Predictive Value of Tests; Reproducibility of Results; Rheumatic Heart Disease | 2016 |
Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Heart Valve Diseases; Humans; Kaplan-Meier Estimate; Male; Medicare; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States | 2016 |
NOACs for Stroke Prevention in Atrial Fibrillation With Valve Disease: Filling the Gaps.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Heart Valve Diseases; Humans; Rivaroxaban; Stroke | 2017 |
Spontaneous ascending aortic intramural haematoma in a patient on dabigatran.
Topics: Administration, Oral; Aged; Anticoagulants; Aortic Diseases; Aortic Valve; Benzimidazoles; beta-Alanine; Blood Vessel Prosthesis Implantation; Chest Pain; Dabigatran; Dyspnea; Female; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Hematoma; Humans; Pericardial Effusion; Risk Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Thrombosis of a mechanical heart valve despite dabigatran.
Topics: Aged; Aortic Valve; Benzimidazoles; Dabigatran; Fibrinolytic Agents; Heart Valve Diseases; Heart Valve Prosthesis; Humans; Male; Off-Label Use; Pyridines; Thrombosis; Treatment Failure | 2012 |
Mechanical valve thrombosis with dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Echocardiography, Transesophageal; Female; Follow-Up Studies; Heart Diseases; Heart Valve Diseases; Heart Valve Prosthesis; Humans; Middle Aged; Prosthesis Failure; Thrombosis | 2012 |